Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$8.818M
TTM
Current Assets
$4.962M
Q3 2024
Current Liabilities
$814.1K
Q3 2024
Current Ratio
609.58%
Q3 2024
Total Assets
$8.379M
Q3 2024
Total Liabilities
$1.774M
Q3 2024
Book Value
$6.605M
Q3 2024
Cash
P/E
-0.3215
Nov 29, 2024 EST
Free Cash Flow
-$8.084M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $10.00K $350.0K $520.0K $1.410M $560.0K
YoY Change -100.0% -97.14% -32.69% -63.12% 151.79%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $10.00K $350.0K $520.0K $1.410M $560.0K
Cost Of Revenue $0.00 $0.00 $170.0K $240.0K $670.0K $260.0K
Gross Profit $0.00 $10.00K $180.0K $280.0K $740.0K $300.0K
Gross Profit Margin 100.0% 51.43% 53.85% 52.48% 53.57%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Selling, General & Admin $5.517M $6.603M $6.016M $5.584M $4.270M $4.020M $2.870M $1.580M $1.270M $950.0K
YoY Change -16.45% 9.77% 7.73% 30.77% 6.22% 40.07% 81.65% 24.41% 33.68%
% of Gross Profit 40200.0% 1594.44% 564.29% 171.62% 316.67%
Research & Development $5.004M $6.554M $5.483M $5.918M $6.580M $4.720M $1.930M $500.0K $1.040M $870.0K
YoY Change -23.66% 19.55% -7.36% -10.06% 39.41% 144.56% 286.0% -51.92% 19.54%
% of Gross Profit 47200.0% 1072.22% 178.57% 140.54% 290.0%
Depreciation & Amortization $123.7K $96.66K $116.2K $99.34K $80.00K $70.00K $60.00K $60.00K $70.00K $40.00K
YoY Change 28.0% -16.84% 17.01% 24.18% 14.29% 16.67% 0.0% -14.29% 75.0%
% of Gross Profit 700.0% 33.33% 21.43% 9.46% 13.33%
Operating Expenses $10.52M $13.16M $11.50M $11.50M $10.84M $8.740M $4.810M $2.070M $2.310M $1.830M
YoY Change -20.04% 14.43% -0.03% 6.11% 24.03% 81.7% 132.37% -10.39% 26.23%
Operating Profit -$10.52M -$13.16M -$11.50M -$11.50M -$10.84M -$8.730M -$4.630M -$1.790M -$1.570M -$1.530M
YoY Change -20.04% 14.43% -0.03% 6.11% 24.17% 88.55% 158.66% 14.01% 2.61%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Interest Expense $0.00 -$230.0K -$2.360M
YoY Change -100.0% -90.25%
% of Operating Profit
Other Income/Expense, Net $460.5K -$21.53K $267.1K -$223.6K -$110.0K -$780.0K -$750.0K -$980.0K -$710.0K -$650.0K
YoY Change -2238.53% -108.06% -219.44% 103.26% -85.9% 4.0% -23.47% 38.03% 9.23%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Pretax Income -$10.06M -$13.18M -$11.23M -$11.73M -$13.31M -$9.800M -$5.380M -$2.780M -$2.280M -$2.180M
YoY Change -23.67% 17.34% -4.22% -11.9% 35.82% 82.16% 93.53% 21.93% 4.59%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.06M -$13.18M -$11.23M -$11.73M -$13.31M -$9.800M -$5.380M -$2.780M -$2.280M -$2.180M
YoY Change -23.67% 17.34% -4.22% -11.9% 35.82% 82.16% 93.53% 21.93% 4.59%
Net Earnings / Revenue -98000.0% -1537.14% -534.62% -161.7% -389.29%
Basic Earnings Per Share -$4.56 -$0.28 -$0.63
Diluted Earnings Per Share -$1.58 -$4.56 -$274.5K -$611.3K -$1.775M -$2.178M -$1.949M -$763.7K -$626.4K -$598.9K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Cash & Short-Term Investments $2.834M $4.889M $9.462M $7.230M $6.170M $6.470M $5.600M $140.0K $20.00K $160.0K
YoY Change -42.04% -48.33% 30.86% 17.18% -4.64% 15.54% 3900.0% 600.0% -87.5%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $198.9K $992.9K $1.348M $400.0K $250.0K $420.0K $80.00K $10.00K $10.00K $10.00K
YoY Change -79.97% -26.34% 237.0% 60.0% -40.48% 425.0% 700.0% 0.0% 0.0%
Inventory $2.645M $1.285M $590.0K $110.0K $60.00K $190.0K $40.00K $100.0K $240.0K
Prepaid Expenses
Receivables $0.00 $10.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.033M $8.527M $12.09M $8.210M $6.540M $6.950M $5.880M $200.0K $130.0K $400.0K
YoY Change -64.43% -29.5% 47.31% 25.54% -5.9% 18.2% 2840.0% 53.85% -67.5%
Property, Plant & Equipment $465.9K $741.5K $774.5K $550.0K $640.0K $270.0K $240.0K $300.0K $360.0K $300.0K
YoY Change -37.17% -4.27% 40.83% -14.06% 137.04% 12.5% -20.0% -16.67% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.255M $5.990K $5.990K $10.00K
YoY Change 54248.25% 0.0% -40.1%
Total Long-Term Assets $3.721M $747.5K $780.5K $550.0K $640.0K $270.0K $240.0K $290.0K $360.0K $300.0K
YoY Change 397.86% -4.24% 41.91% -14.06% 137.04% 12.5% -17.24% -19.44% 20.0%
Total Assets $6.754M $9.274M $12.87M $8.760M $7.180M $7.220M $6.120M $490.0K $490.0K $700.0K
YoY Change
Accounts Payable $360.4K $614.0K $791.1K $400.0K $1.280M $630.0K $780.0K $230.0K $80.00K $10.00K
YoY Change -41.3% -22.39% 97.76% -68.75% 103.17% -19.23% 239.13% 187.5% 700.0%
Accrued Expenses $514.2K $1.061M $752.7K $580.0K $500.0K $290.0K $70.00K $210.0K $160.0K $90.00K
YoY Change -51.55% 40.99% 29.78% 16.0% 72.41% 314.29% -66.67% 31.25% 77.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $300.0K $0.00 $0.00 $950.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $28.48K $28.48K
YoY Change 0.0%
Total Short-Term Liabilities $903.1K $1.704M $1.544M $990.0K $2.070M $970.0K $850.0K $1.380M $240.0K $100.0K
YoY Change -46.99% 10.36% 55.94% -52.17% 113.4% 14.12% -38.41% 475.0% 140.0%
Long-Term Debt $0.00 $0.00 $28.48K $340.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -91.62%
Other Long-Term Liabilities $192.1K $365.9K $518.2K $270.0K $340.0K
YoY Change -47.51% -29.38% 91.91% -20.59%
Total Long-Term Liabilities $192.1K $365.9K $546.6K $610.0K $340.0K $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -47.51% -33.06% -10.39% 79.41%
Total Liabilities $1.095M $2.070M $2.090M $1.600M $2.420M $970.0K $850.0K $1.380M $240.0K $100.0K
YoY Change -47.08% -0.99% 30.65% -33.88% 149.48% 14.12% -38.41% 475.0% 140.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.8349 Million

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Ann Arbor, Michigan and currently employs 21 full-time employees. The company went IPO on 2017-06-28. ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The firm's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. The company is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: ABBOTT LABORATORIES Acutus Medical, Inc. ALR TECHNOLOGIES INC. RemSleep Holdings Inc. BIOLASE, INC EKSO BIONICS HOLDINGS, INC. HeartBeam, Inc. NeuroMetrix, Inc. PetVivo Holdings, Inc. VASO Corp